{"id":4155,"date":"2024-04-26T10:50:39","date_gmt":"2024-04-26T02:50:39","guid":{"rendered":"https:\/\/flcube.com\/?p=4155"},"modified":"2024-10-24T00:18:36","modified_gmt":"2024-10-23T16:18:36","slug":"sanofi-reports-6-7-yoy-sales-growth-in-q1-2024-driven-by-dupixent-and-new-product-launches","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=4155","title":{"rendered":"Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches"},"content":{"rendered":"\n<p>France-based pharmaceutical giant Sanofi (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>) has reported its financial results for the first quarter of 2024, with sales increasing by 6.7% year-on-year (YOY) in constant exchange rate terms to \u20ac10.46 billion (USD 11.23 billion). The biopharma segment experienced growth of 6.3%, with pharmaceutical sales rising by 6.4% to \u20ac7.76 billion (USD 8.33 billion) and vaccines seeing a 5.6% increase to \u20ac1.18 billion (USD 1.27 billion). The consumer healthcare unit also performed well, with a 9% increase in sales reaching \u20ac1.53 billion (USD 1.64 billion).<\/p>\n\n\n\n<p>Key growth drivers for the quarter included the anti-inflammatory disease drug Dupixent (dupilumab), which saw sales surge by 24.9% to \u20ac2.84 billion (USD 3.04 billion). The Rest of World sales, led by the China market, were the fastest-growing segment at +67.5% YOY.<\/p>\n\n\n\n<p>New product launches also contributed significantly to the growth, with a 90.5% YOY expansion to \u20ac606 million (USD 650.4 million), driven by Nexviazyme (avalglucosidase alfa) for late-onset Pompe disease and ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein] for hemophilia.<\/p>\n\n\n\n<p>In the China market, sales were up 6.2%, propelled by Dupixent, blood thinner Plavix (clopidogrel), and diabetes drug Toujeo (insulin glargine). Toujeo&#8217;s China sales have now exceeded those of Sanofi\u2019s first-generation insulin product Lantus as patients switched products. Cholesterol-lowering Praluent (alirocumab) and thymoglobulin also contributed to the growth. However, global sales of deep-vein thrombosis prophylactic Lovenox (enoxaparin) declined by -13% due to the drug\u2019s inclusion in China\u2019s volume-based procurement program.<\/p>\n\n\n\n<p>Sanofi&#8217;s CEO, Paul Hudson, described the results as an &#8220;excellent&#8221; start to the year. The company is also awaiting potential milestone regulatory decisions for Dupixent as a treatment for chronic obstructive pulmonary disorder (COPD). The US FDA PDUFA action date for this decision is set for June 27, 2024, with filings under review in all major markets, including China.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has reported its financial results for the first quarter&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,867,147],"class_list":["post-4155","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-nasdaq-sny","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has reported its financial results for the first quarter of 2024, with sales increasing by 6.7% year-on-year (YOY) in constant exchange rate terms to \u20ac10.46 billion (USD 11.23 billion). The biopharma segment experienced growth of 6.3%, with pharmaceutical sales rising by 6.4% to \u20ac7.76 billion (USD 8.33 billion) and vaccines seeing a 5.6% increase to \u20ac1.18 billion (USD 1.27 billion). The consumer healthcare unit also performed well, with a 9% increase in sales reaching \u20ac1.53 billion (USD 1.64 billion).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=4155\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=4155\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-26T02:50:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-23T16:18:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4155#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4155\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches\",\"datePublished\":\"2024-04-26T02:50:39+00:00\",\"dateModified\":\"2024-10-23T16:18:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4155\"},\"wordCount\":293,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"NASDAQ: SNY\",\"Sanofi\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=4155#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4155\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=4155\",\"name\":\"Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-04-26T02:50:39+00:00\",\"dateModified\":\"2024-10-23T16:18:36+00:00\",\"description\":\"France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has reported its financial results for the first quarter of 2024, with sales increasing by 6.7% year-on-year (YOY) in constant exchange rate terms to \u20ac10.46 billion (USD 11.23 billion). The biopharma segment experienced growth of 6.3%, with pharmaceutical sales rising by 6.4% to \u20ac7.76 billion (USD 8.33 billion) and vaccines seeing a 5.6% increase to \u20ac1.18 billion (USD 1.27 billion). The consumer healthcare unit also performed well, with a 9% increase in sales reaching \u20ac1.53 billion (USD 1.64 billion).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4155#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=4155\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4155#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches - Insight, China&#039;s Pharmaceutical Industry","description":"France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has reported its financial results for the first quarter of 2024, with sales increasing by 6.7% year-on-year (YOY) in constant exchange rate terms to \u20ac10.46 billion (USD 11.23 billion). The biopharma segment experienced growth of 6.3%, with pharmaceutical sales rising by 6.4% to \u20ac7.76 billion (USD 8.33 billion) and vaccines seeing a 5.6% increase to \u20ac1.18 billion (USD 1.27 billion). The consumer healthcare unit also performed well, with a 9% increase in sales reaching \u20ac1.53 billion (USD 1.64 billion).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=4155","og_locale":"en_US","og_type":"article","og_title":"Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=4155","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-04-26T02:50:39+00:00","article_modified_time":"2024-10-23T16:18:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=4155#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=4155"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches","datePublished":"2024-04-26T02:50:39+00:00","dateModified":"2024-10-23T16:18:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=4155"},"wordCount":293,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","NASDAQ: SNY","Sanofi"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=4155#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=4155","url":"https:\/\/flcube.com\/?p=4155","name":"Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-04-26T02:50:39+00:00","dateModified":"2024-10-23T16:18:36+00:00","description":"France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has reported its financial results for the first quarter of 2024, with sales increasing by 6.7% year-on-year (YOY) in constant exchange rate terms to \u20ac10.46 billion (USD 11.23 billion). The biopharma segment experienced growth of 6.3%, with pharmaceutical sales rising by 6.4% to \u20ac7.76 billion (USD 8.33 billion) and vaccines seeing a 5.6% increase to \u20ac1.18 billion (USD 1.27 billion). The consumer healthcare unit also performed well, with a 9% increase in sales reaching \u20ac1.53 billion (USD 1.64 billion).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=4155#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=4155"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=4155#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4155","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4155"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4155\/revisions"}],"predecessor-version":[{"id":9158,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4155\/revisions\/9158"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4155"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4155"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4155"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}